Johnson & Johnson (JNJ) Long-Term Debt Issuances (2009 - 2025)
Johnson & Johnson's (JNJ) quarterly Long-Term Debt Issuances came in at $9.1 billion in Q1 2025, up 456800.0% year-on-year from N/an in Q1 2024, and up 913700.0% quarter-over-quarter from $1.0 million in Q3 2024.
Johnson & Johnson (JNJ) Long-Term Debt Issuances (2009 - 2025) Analysis & Trends
Johnson & Johnson has disclosed Long-Term Debt Issuances across 15 years of filings, most recently posting $9.1 billion for Q1 2025.
- Long-Term Debt Issuances for Q1 2025 came in at $9.1 billion, up 456800.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.1 billion (up 37.21% YoY), and the FY2025 annual result was $9.1 billion, up 37.21% from the prior year.
- Long-Term Debt Issuances came in at $9.1 billion for Q1 2025 at Johnson & Johnson, up from $1.0 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $9.1 billion in Q1 2025 to a low of -$7.7 billion in Q4 2023.
- The 4-year median for Long-Term Debt Issuances is $2.0 million (2021), against an average of $1.8 billion.
- Across the five-year window, Long-Term Debt Issuances tumbled 99.97% in 2024 and soared 456800.0% in 2025, its largest moves.
- Johnson & Johnson's Long-Term Debt Issuances stood at $2.0 million in 2021, then tumbled by 383800.0% to -$7.7 billion in 2023, then soared by 100.01% to $1.0 million in 2024, then surged by 913700.0% to $9.1 billion in 2025.
- The last three Long-Term Debt Issuances figures came in at $9.1 billion (Q1 2025), $1.0 million (Q3 2024), and $6.7 billion (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 30, 2025 | 9.14 Bn |
| Mar 30, 2025 | 9.14 Bn |
| Sep 29, 2024 | 1.00 Mn |
| Sep 29, 2024 | 1.00 Mn |
| Jun 30, 2024 | 6.66 Bn |
| Jun 30, 2024 | 6.66 Bn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Oct 1, 2023 | -7.67 Bn |
| Oct 1, 2023 | -7.67 Bn |
| Apr 2, 2023 | 7.67 Bn |
| Apr 2, 2023 | 7.67 Bn |
| Jan 1, 2023 | -1.00 Mn |
| Jan 1, 2023 | -1.00 Mn |
| Oct 3, 2021 | 2.00 Mn |
| Oct 3, 2021 | 2.00 Mn |
| Apr 4, 2021 | 1.00 Mn |
| Apr 4, 2021 | 1.00 Mn |
| Sep 27, 2020 | 7.43 Bn |
| Sep 27, 2020 | 7.43 Bn |